Brian Orelli, PhD

Targeting BCMA is all the rage, but who will come out on top?

Drugmakers are targeting B-cell maturation antigen in different ways.

The battle for beta thalassemia and sickle cell disease patients is heating up.

Don't call it an approval -- yet.

The biotech has a plan to increase profitability.

The new version is more potent, and therefore requires a lower dose.

Pharmaceutical companies are looking to bolster their pipelines.

Combining vaccines for multiple viruses could boost sales.

Multiple drugmakers gained FDA approval last week.

Not everything is coming up roses for the industry.

Don't forget about the biotech's long-term valuation.

Consider the outlook for the rest of the company's units before investing.

Government contracts are important for the initial wave of revenue.

The biotech's sleep drug Hetlioz gained an expanded approval.

The differences could define the eventual winner.

The differences between the vaccines could affect the eventual winner (if there is one).

Experts break down the company's phase 3 data.

The outside experts will give their opinions in a couple of weeks.

Its vaccine candidate, mRNA-1273, still needs to be approved by health regulators.

The biotech has multiple potential clinical readouts for its COVI-19 products in the months ahead, but investors should also keep an eye on the company's cash reserves.